Torrent Pharmaceuticals Income Statement

Financials in millions INR. Fiscal year is April - March.

Millions INR. Fiscal year is Apr - Mar.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec '25 Dec 31, 2025	Mar '25 Mar 31, 2025	Mar '24 Mar 31, 2024	Mar '23 Mar 31, 2023	Mar '22 Mar 31, 2022	Mar '21 Mar 31, 2021
Revenue	127,421	115,161	107,278	96,202	85,080	80,046
Revenue Growth (YoY)	12.74%	7.35%	11.51%	13.07%	6.29%	0.82%
Cost of Revenue	31,039	27,759	26,862	27,352	24,420	21,464
Gross Profit	96,382	87,402	80,416	68,850	60,660	58,582
Selling, General & Admin	25,118	22,708	20,166	17,052	15,483	14,597
Other Operating Expenses	29,594	27,484	26,573	23,377	20,865	19,184
Operating Expenses	62,831	58,141	54,693	47,449	42,967	40,354
Operating Income	33,551	29,261	25,724	21,400	17,693	18,228
Interest Expense	-2,044	-2,514	-3,526	-3,322	-2,529	-3,508
Interest & Investment Income	201.9	201.9	114.8	147.8	71.5	50.7
Currency Exchange Gain (Loss)	-166.1	-166.1	-39.1	-180.8	1,695	319.7
Other Non Operating Income (Expenses)	-1,173	6.9	314.4	61.1	76	21.7
EBT Excluding Unusual Items	30,370	26,790	22,587	18,106	17,007	15,112
Merger & Restructuring Charges	-	-	-	-	-4,847	-
Gain (Loss) on Sale of Investments	167.3	167.3	179.9	195.1	101.4	155.8
Gain (Loss) on Sale of Assets	13.4	13.4	-0.2	216.2	-	-
Asset Writedown	-	-	-129.7	-45.6	-2.3	-4.8
Other Unusual Items	-472.1	-242.1	883.8	-	-	-
Pretax Income	30,078	26,728	23,521	18,472	12,259	15,263
Income Tax Expense	7,356	7,616	6,957	6,019	4,487	2,744
Earnings From Continuing Operations	22,723	19,113	16,564	12,452	7,772	12,519
Net Income	22,723	19,113	16,564	12,452	7,772	12,519
Net Income to Common	22,723	19,113	16,564	12,452	7,772	12,519
Net Income Growth	22.01%	15.39%	33.02%	60.22%	-37.92%	22.17%
Shares Outstanding (Basic)	339	338	338	338	338	338
Shares Outstanding (Diluted)	339	338	338	338	338	338
EPS (Basic)	67.12	56.47	48.94	36.79	22.96	36.99
EPS (Diluted)	67.12	56.47	48.94	36.79	22.96	36.99
EPS Growth	21.97%	15.39%	33.02%	60.22%	-37.92%	22.17%
Free Cash Flow	-	19,732	28,333	17,942	16,004	16,702
Free Cash Flow Per Share	-	58.30	83.72	53.01	47.29	49.35
Dividend Per Share	35.000	32.000	28.000	22.000	16.500	17.500
Dividend Growth	9.38%	14.29%	27.27%	33.33%	-5.71%	105.88%
Gross Margin	75.64%	75.89%	74.96%	71.57%	71.30%	73.19%
Operating Margin	26.33%	25.41%	23.98%	22.25%	20.80%	22.77%
Profit Margin	17.83%	16.60%	15.44%	12.94%	9.13%	15.64%
Free Cash Flow Margin	-	17.14%	26.41%	18.65%	18.81%	20.87%
EBITDA	41,027	36,758	33,249	28,026	23,823	24,291
EBITDA Margin	32.20%	31.92%	30.99%	29.13%	28.00%	30.35%
D&A For EBITDA	7,477	7,498	7,526	6,626	6,130	6,063
EBIT	33,551	29,261	25,724	21,400	17,693	18,228
EBIT Margin	26.33%	25.41%	23.98%	22.25%	20.80%	22.77%
Effective Tax Rate	24.45%	28.49%	29.58%	32.59%	36.60%	17.98%
Revenue as Reported	126,474	115,394	107,858	96,653	87,046	80,615

Updated Dec 31, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.